Xipag ®
A nutraceutical product conceived and patented by idi pharma, designed to address needs that cannot be met with conventional treatments.
At idi pharma, we believe in research and scientific rigor.
Contribute to advancing knowledge on the applications of XIPAG®.
The Project
The scientific community increasingly adopts the nutraceutical approach to achieve specific objectives. However, the wide variety of nutraceutical formulations and ingredients does not always correspond to an equally broad range of approaches capable of truly meeting the needs of the individual subject, due to a lack of information derived from scientific studies. XIPAG® LAB was created to promote scientific research on the use of this nutraceutical, support researchers, and build a network for high-value content.
Projects
that have been evaluated
1
Studies
that have been published
1
Patients
involved
1
Contact Us
Fill out the dedicated form to describe your research project idea. Your proposal will be evaluated by a scientific board, which may express interest and contribute to the implementation of the study.Appuntamenti
Roma
4 Aprile 2025
Publications
Year 2022Title Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
First Author L. Muraca
Year 2025
Title Discovering a new nutraceutical based on pollen extract and teupolioside: A prospective monocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients
First Author M. Lo Re, M. Pezzoli
Year 2025
Title Quantification of the Role of Teupol® 25P and Graminex® G96 Compared to Hexanic Extract of Serenoa repens in Patients Affected by Lower Urinary Tract Symptoms During Treatment with Silodosin
First Author Y. Al Salhi
Year 2025
Title The Nrf2-Related Pathways and the Antiandrogenic Effects Are Enhanced In Vitro and In Silico by the Combination of Graminex® G96® Pollen and Teupol 25P in Cell Models of Benign Prostate Hyperplasia
First Author N. Mencarelli, V. Consoli
Year 2025
Title Sexual safety and efficacy of a pollen extract and teupolioside-based supplement in men with benign prostatic hyperplasia: A prospective observational study
First Author M. Vittori, V. Iacovelli
Year 2025
Title Teupolioside and Graminex (Xipag®) combined therapy induced anti-inflammatory effects and decreased dihydrotestosterone levels in the prostate tissue of patients with benign prostate hyperplasia: results of a pilot study
First Author R. Bartoletti